(Q51738566)

English

Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy).

scientific article published on 18 December 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170646%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170646%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

0 references

0 references

expanded access

1 reference

based on heuristic

inferred from title

Diana Giannarelli

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170646%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170646%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Riccardo Danielli

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170646%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170646%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Anna Maria Di Giacomo

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170646%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Erica Bertocci

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170646%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Chiara Nannicini

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170646%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Angelo Balestrazzi

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170646%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Francesco Vigni

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170646%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Valentina Riversi

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170646%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Clelia Miracco

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170646%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Maurizio Biagioli

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170646%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Maresa Altomonte

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170646%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

18 December 2010

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170646%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170646%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

60

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170646%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170646%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

467-477

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170646%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

https://scigraph.springernature.com/pub.10.1007/s00262-010-0958-2

0 references

Cutaneous melanoma: available therapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0958-2

21 January 2018

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0958-2

21 January 2018

Novel therapeutics for melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0958-2

21 January 2018

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0958-2

21 January 2018

Update on anti-CTLA-4 antibodies in clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0958-2

21 January 2018

Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0958-2

21 January 2018

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0958-2

21 January 2018

Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0958-2

21 January 2018

Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0958-2

21 January 2018

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0958-2

21 January 2018

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0958-2

21 January 2018

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0958-2

21 January 2018

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0958-2

21 January 2018

Ipilimumab for advanced melanoma: a nursing perspective

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0958-2

21 January 2018

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0958-2

21 January 2018

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0958-2

21 January 2018

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0958-2

21 January 2018

The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0958-2

21 January 2018

Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0958-2

21 January 2018

Identifiers

10.1007/S00262-010-0958-2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170646%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170646%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51738566&oldid=1226034658"